Marie Sanchirico takes charge of Medical Affairs at Upstream Bio Inc. to drive physician engagement

Marie Sanchirico takes charge of Medical Affairs at Upstream Bio Inc. to drive physician engagement
Upstream Bio appoints new Medical Affairs lead

Upstream Bio Inc. has named Marie Sanchirico, PhD, MBA, as head of Medical Affairs in a move designed to enhance its engagement with physicians and scientific experts.

Sanchirico will be instrumental in advancing initiatives that aim to improve care for patients affected by severe inflammatory respiratory diseases. Her appointment signals the company’s commitment to building deeper collaborations with key stakeholders in the medical community.

Upstream Bio recently posted its second quarter 2026 results and announced trial updates, with its stock rising 2.6% to $7.44 following the news on the day of the release. The company is also planning to start Phase 3 trials for severe asthma and CRSwNP in early 2027 according to its announced timeline. These developments follow a period of expanded pipeline activity.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.